| 1 |
34548228 | A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation. | 2022 Mar |
1 |
| 2 |
35105467 | [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma]. | 2022 Mar |
1 |
| 3 |
33454089 | Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib. | 2021 Oct |
1 |
| 4 |
33712615 | Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. | 2021 Mar 12 |
2 |
| 5 |
33865115 | Complex renal cysts combined with hemorrhage during crizotinib treatment for ALK-rearranged lung adenocarcinoma. | 2021 |
1 |
| 6 |
33976623 | Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. | 2021 Jan-Apr |
1 |
| 7 |
34124783 | AZD8055 enhances in vivo efficacy of afatinib in chordomas. | 2021 Sep |
1 |
| 8 |
34298655 | Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance. | 2021 Jul 9 |
1 |
| 9 |
34322251 | Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification. | 2021 Jul |
1 |
| 10 |
34392186 | Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. | 2021 Oct |
1 |
| 11 |
34397683 | Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report. | 2021 Jul 30 |
3 |
| 12 |
34428672 | Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. | 2021 Dec 1 |
1 |
| 13 |
34660287 | A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. | 2021 |
1 |
| 14 |
34957368 | Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. | 2021 |
1 |
| 15 |
32122695 | A case treated with Crizotinib after secondary MET amplification of A double Rare L747S and G719S EGFR mutation Pulmonary Sarcomatoid Carcinoma. | 2020 Apr |
1 |
| 16 |
32540560 | The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. | 2020 Aug |
6 |
| 17 |
32620469 | Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report. | 2020 Nov |
1 |
| 18 |
32648452 | Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report. | 2020 Sep |
2 |
| 19 |
32942985 | Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options. | 2020 Sep 17 |
1 |
| 20 |
33037240 | Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing. | 2020 Oct 9 |
1 |
| 21 |
30422759 | Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance. | 2019 |
1 |
| 22 |
30791921 | Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study. | 2019 Feb 21 |
7 |
| 23 |
30797494 | Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib. | 2019 Mar |
1 |
| 24 |
30881166 | Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification. | 2019 |
1 |
| 25 |
30922580 | Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib. | 2019 Apr |
1 |
| 26 |
31078602 | Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. | 2019 Aug |
1 |
| 27 |
31131689 | De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors. | 2019 |
1 |
| 28 |
31235037 | Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing. | 2019 Jul |
1 |
| 29 |
31506424 | Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. | 2019 Sep 10 |
1 |
| 30 |
29128427 | Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. | 2018 Apr |
1 |
| 31 |
29505507 | Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report. | 2018 Jan |
2 |
| 32 |
29573824 | Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma. | 2018 Oct |
1 |
| 33 |
29764505 | Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. | 2018 May 9 |
1 |
| 34 |
30053332 | Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. | 2018 Oct |
1 |
| 35 |
30268451 | Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses. | 2018 Oct |
8 |
| 36 |
30368417 | Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. | 2018 Nov |
2 |
| 37 |
30381567 | Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib. | 2018 Nov-Dec |
1 |
| 38 |
27697581 | Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. | 2017 Jan |
1 |
| 39 |
27707887 | Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. | 2017 Jan |
1 |
| 40 |
28007627 | Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). | 2017 Apr |
1 |
| 41 |
28271038 | Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. | 2017 |
2 |
| 42 |
28337371 | Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma. | 2017 |
1 |
| 43 |
28499860 | Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. | 2017 Oct |
1 |
| 44 |
28721068 | Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report. | 2017 |
1 |
| 45 |
28781781 | Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature. | 2017 Aug |
2 |
| 46 |
28961830 | Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C. | 2017 Oct 1 |
1 |
| 47 |
26381283 | EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect. | 2016 Jan |
2 |
| 48 |
26811689 | Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor. | 2016 |
2 |
| 49 |
26845121 | Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor. | 2016 Feb |
1 |
| 50 |
26988570 | Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. | 2016 Jul |
1 |